ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury
ROS-чувствительная нанотранспортная система доставки лекарственного средства, сочетающая нацеленные на митохондрии наночастицы диоксида церия с аторвастатином, для лечения острого повреждения почек
2020-01-01
SCID: 54.1/mnzszam3
Discuss with AI
AtorvastatinMitochondria-targeting ceria nanoparticlesOxidative stressROS-responsive drug deliverySepsis-induced acute kidney injury
Figures from the paper
Abstract (AI)
Acute kidney injury (AKI) caused by sepsis is a serious disease which mitochondrial oxidative stress and inflammatory play a key role in its pathophysiology.Ceria nanoparticles hold strong and recyclable reactive oxygen species (ROS)-scavenging activity, have been applied to treat ROS-related diseases.However, ceria nanoparticles can't selectively target mitochondria and the ultra-small ceria nanoparticles are easily agglomerated.To overcome these shortcomings and improve therapeutic efficiency, we designed an ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury.Methods: Ceria nanoparticles were modified with triphenylphosphine (TCeria NPs), followed by coating with ROS-responsive organic polymer (mPEG-TK-PLGA) and loaded atorvastatin (Atv/PTP-TCeria NPs).The physicochemical properties, in vitro drug release profiles, mitochondria-targeting ability, in vitro antioxidant, anti-apoptotic activity and in vivo treatment efficacy of Atv/PTP-TCeria NPs were examined.Results: Atv/PTP-TCeria NPs could accumulate in kidneys and hold a great ability to ROS-responsively release drug and TCeria NPs could target mitochondria to eliminate excessive ROS.In vitro study suggested Atv/PTP-TCeria NPs exhibited superior antioxidant and anti-apoptotic activity.In vivo study showed that Atv/PTP-TCeria NPs effectively decreased oxidative stress and inflammatory, could protect the mitochondrial structure, reduced apoptosis of tubular cell and tubular necrosis in the sepsis-induced AKI mice model.Conclusions: This ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin has favorable potentials in the sepsis-induced AKI therapy.
Key Findings
1
An ROS-responsive nanodrug system combined mitochondria-targeting ceria nanoparticles with atorvastatin for treating sepsis-induced acute kidney injury.
2
In septic AKI mice, treatment reduced oxidative stress, inflammation, tubular-cell apoptosis, and tubular necrosis while preserving mitochondrial structure.
3
The combined delivery system showed favorable therapeutic potential for sepsis-induced acute kidney injury.
4
The formulation accumulated in kidneys and demonstrated strong ROS-scavenging, antioxidant, and anti-apoptotic activity in vitro.
5
Triphenylphosphine-modified ceria nanoparticles targeted mitochondria, while the ROS-responsive polymer enabled release of atorvastatin and ceria nanoparticles under oxidative conditions.
Research Object
ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for sepsis-induced acute kidney injury
Research Subject
Its mitochondria-targeting, ROS-responsive drug release, antioxidant and anti-apoptotic activity, and therapeutic efficacy in sepsis-induced acute kidney injury
Publication Details
Publication Date
2020-01-01
Journal
Publisher
ISSN
Cited by
376
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes2013
Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles2007
Pharmacological potential of cerium oxide nanoparticles2011
Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease2016
Ceria Nanoparticles that can Protect against Ischemic Stroke2012
Toxicity of Cerium Oxide Nanoparticles in Human Lung Cancer Cells2006
Simultaneous Blood–Brain Barrier Crossing and Protection for Stroke Treatment Based on Edaravone-Loaded Ceria Nanoparticles2018